Selecta Biosciences, Inc.
(NASDAQ : SELB)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
AMGNAmgen, Inc. -0.30%242.581.5%$876.52m
MRNAModerna, Inc. 3.84%148.340.0%$801.99m
VRTXVertex Pharmaceuticals, Inc. 0.09%282.031.9%$480.24m
GILDGilead Sciences, Inc. -0.36%61.591.0%$473.71m
REGNRegeneron Pharmaceuticals, Inc. -0.41%588.722.6%$469.74m
NVAXNovavax, Inc. 9.28%56.2075.7%$435.48m
ILMNIllumina, Inc. 1.79%187.663.3%$341.87m
SNSSSunesis Pharmaceuticals, Inc. -4.64%3.700.7%$258.64m
BIIBBiogen, Inc. 1.02%206.011.8%$240.49m
BNTXBioNTech SE 4.12%155.240.0%$194.86m
CRSPCRISPR Therapeutics AG 2.03%62.010.6%$163.36m
BMRNBioMarin Pharmaceutical, Inc. 0.56%83.334.2%$116.83m
EXASEXACT Sciences Corp. 2.41%40.3417.7%$93.12m
IOVAIovance Biotherapeutics, Inc. 1.81%11.240.0%$89.70m
TECHBio-Techne Corp. -0.10%346.314.5%$89.53m

Company Profile

Selecta Biosciences, Inc. operates as a clinical-stage biopharmaceutical company, which engages in the research and development of nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. It produces the Synthetic Vaccine Particles (SVP) platform for immune tolerance and immune stimulation. The firm's proprietary pipeline includes SVP-enabled enzyme, oncology and gene therapies. The company was founded by Omid C. Farokhzad, Robert S. Langer Jr., and Ulrich von Andrian in 2007 and is headquartered in Watertown, MA.